A5043920233- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Biosimilars and Bioanalytical Methods
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Integrated Circuits and Semiconductor Failure Analysis
- Cutaneous lymphoproliferative disorders research
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Phagocytosis and Immune Regulation
- CNS Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Viral-associated cancers and disorders
- Galectins and Cancer Biology
- Cancer-related Molecular Pathways
- Glioma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Biomedical Ethics and Regulation
- Lung Cancer Treatments and Mutations
- Cell death mechanisms and regulation
Universitat Autònoma de Barcelona
2013-2025
Vall d'Hebron Hospital Universitari
2015-2024
Hebron University
2020-2024
Vall d'Hebron Institute of Oncology
2017-2024
Vall d'Hebron Institut de Recerca
2011-2024
<h3>Background</h3> CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity burden CAR-T. The recently developed CAR-HEMATOTOX (HT) score—composed five pre-lymphodepletion variables (eg, absolute neutrophil count, platelet hemoglobin, C-reactive protein, ferritin)—enables risk stratification hematological...
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety efficacy of axi-cel tisa-cel outside the setting clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis or were retrospectively collected 12 Spanish centers. A total 307 (n=152) (n=155) November 2018 August 2021, which...
Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous exposure.
The levels of cell free circulating tumor DNA (ctDNA) in plasma correlated with treatment response and outcome systemic lymphomas. Notably, brain tumors, the ctDNA cerebrospinal fluid (CSF) are higher than plasma. Nevertheless, their role central nervous system (CNS) lymphomas remains elusive. We evaluated CSF from 19 patients: 6 restricted CNS lymphomas, 1 lymphoma, 12 performed whole exome sequencing or targeted to identify somatic mutations primary tumor, then variant-specific droplet...
Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro vivo antileukemic activity. This study aimed to determine safety tolerability iadademstat as monotherapy patients relapsed/refractory acute myeloid leukemia (R/R AML).
ABSTRACT Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose this study was to identify risk factors and long-term outcomes after AKI who received CAR T-cell therapy. Methods Medical records 115 adult R/R hematological malignancies treated CD19-targeted T-cells at Vall d'Hebron University Hospital between July 2018 May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI),...
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, may enhance cytotoxic of rituximab. Here we report results patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular (FL), other lymphomas, phase 1 studies evaluating urelumab alone (NCT01471210) combined rituximab (NCT01775631). Sixty received (0.3 mg/kg IV Q3W, 8 mg Q6W); 46 (0.1 mg/kg, 0.3 Q3W)...
Abstract Purpose: This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53–MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Patients and Methods: Initial dosing regimens were: 1A (day 1; 21-day cycle; 12.5–350 mg) 2A (days 1–14; 28-day 1–20 mg). Alternative included 1B 1 8; cycle) 2C 1–7; cycle). The primary endpoint was incidence dose-limiting toxicities (DLT) during cycle 1. Results: Overall, 115...
Data are scarce on cytomegalovirus (CMV) replication in patients receiving CD19-directed chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity, and management of CMV infection with aggressive B lymphoma treated CAR therapy. In this retrospective observational study, analyzed viral load its clinical impact therapy between July 2018 December 2021 at a single center. Patients negative baseline IgG or previous allogeneic stem transplantation were excluded....
// Noelia Purroy 1 , Pau Abrisqueta Júlia Carabia Cecilia Carpio Carles Palacio Francesc Bosch 1,* and Marta Crespo Laboratory of Experimental Hematology, Department Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain * These authors contributed equally to this work Correspondence: Crespo, email: Keywords : CLL, co-culture, proliferation, immunophenotype, chemoresistance, ZAP-70 Received September 19, 2014 Accepted December 02, Published 03, Abstract Chronic...
Abstract Bromodomain and extraterminal proteins (BET) play key roles in regulation of gene expression, may a role cancer-cell proliferation, survival, oncogenic progression. CC-90010-ST-001 (NCT03220347) is an open-label phase I study trotabresib, oral BET inhibitor, heavily pretreated patients with advanced solid tumors relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Primary endpoints were the safety, tolerability, maximum tolerated dose, RP2D trotabresib. Secondary clinical...
Chronic lymphocytic leukemia (CLL) cells are highly dependent on microenvironment, being the BCR pathway one key player in this crosstalk. Among proteins participating, ZAP-70 enhances response to microenvironmental stimuli. MicroRNA-21 (miR-21) is overexpressed diverse neoplasias including CLL, where it has been associated refractoriness fludarabine and shorter time progression survival. To further elucidate role of biology we studied its involvement miR-21 regulation. MiR-21 expression was...
Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory classical Hodgkin lymphoma (cHL). However, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation therapy in these patients remains controversial. We performed a retrospective analysis data from 74 treated with nivolumab. The overall response rate was 58% (including 30.6% complete responses). Treatment-related adverse events were reported 56.8% (grade ≥3 9.4%)....